ImmunoPrecise Antibodies Ltd. (IPA)

Market Cap	49.88M
Revenue (ttm)	16.58M
Net Income (ttm)	-32.30M
Shares Out	45.77M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,077,415
Open	1.040
Previous Close	1.060
Day's Range	1.040 - 1.150
52-Week Range	0.270 - 1.160
Beta	0.22
Analysts	Strong Buy
Price Target	4.00 (+266.97%)
Earnings Date	Jul 28, 2025

About IPA

ImmunoPrecise Antibodies Ltd. operates as a techbio company. It leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies; and support the discovery and development of therapeutic antibodies. The company’s contract research organizations services include B cell Select platforms that enable antibody screening directly from B cells, facilitating the analysis of a set of antibodies, as well as for screening compared to traditional technologies; phage display services that are based...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 3, 2017
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: IPA
• Website: https://www.ipatherapeutics.com

Financial Performance

In 2024, ImmunoPrecise Antibodies's revenue was 24.52 million, an increase of 18.65% compared to the previous year's 20.67 million. Losses were -27.18 million, 2.32% more than in 2023.

Financial numbers in CAD

Analyst Summary

According to 2 analysts, the average rating for IPA stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 266.97% from the latest price.

Price Target

$4.0

(266.97% upside)

Analyst Consensus: Strong Buy